Globus Medical Reports Fourth Quarter and Full Year 2024 Results
AUDUBON, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced...
Epidemics
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen...
Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals
At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended...
Universal Technical Institute Reports Fiscal Year 2025 First Quarter Results
Delivers Financial and Operational Outperformance in Fiscal Q1; Raises Fiscal 2025 Guidance Ranges for All Metrics PHOENIX, Feb. 5, 2025...
HCA Healthcare Reports Fourth Quarter 2024 Results and Provides 2025 Guidance
NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the fourth quarter ended December 31,...
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T.SCOTTSDALE, Ariz., Jan. 23,...
Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva”...
DHS Awards ICF New $40M Digital Engagement Task Order
Collaboration Will Enhance Strategic and Digital Communications and Engagement to Combat Human Trafficking RESTON, Va., Jan. 13, 2025 /PRNewswire/ --...
TOMI Environmental Solutions Positioned to Address Growing Global Disease Threats with SteraMist Technology
Company Expands Reach to Government, Commercial Entities, and School Districts Amid Rising Concerns Over Spread of Respiratory Viruses such as...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase...
MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing...
NHI Announces Updates to Corporate Governance
MURFREESBORO, TN / ACCESSWIRE / January 8, 2025 / National Health Investors, Inc. (NYSE:NHI) announced a series of changes to...
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
Webinar to be held Wednesday, January 8, 2025, at 8am ESTREDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Jasper...
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE,...
Vireo Growth Inc. Announces Closing of Oversubscribed US$81 Million Equity Securities Offering
– Oversubscribed equity raise at US$0.625 per share capitalizes Company with a strong balance sheet– – Financing enables Vireo to...
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today,...
Vireo Growth Inc. Announces $75 Million Financing and Acquisitions of Four Single State Operators
– $75 million equity financing at $0.625 per Vireo share will result in combined new entity having an industry-leading balance...
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with...
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed...